Our findings indicate that preventing TBK1 and IKKε recruitment to the TNF signaling complex, thereby blocking RIPK1 pro-survival phosphorylation and promoting direct RIPK1 activation, is a tractable strategy to increase tumor sensitivity to immune cell killing and has the potential to benefit current immunotherapy interventions. This evidence concerns the gene RIPK1 and neoplasm.